How to improve R&D productivity: the pharmaceutical industry's grand challenge

被引:2271
作者
Paul, Steven M. [1 ]
Mytelka, Daniel S. [1 ]
Dunwiddie, Christopher T. [1 ]
Persinger, Charles C. [1 ]
Munos, Bernard H. [1 ]
Lindborg, Stacy R. [1 ]
Schacht, Aaron L. [1 ]
机构
[1] Eli Lilly & Co, Lilly Res Labs, Lilly Corp Ctr, Indianapolis, IN 46285 USA
关键词
CHOLESTEROL; PCSK9; LDL; DISCOVERY; ATTRITION; MUTATIONS;
D O I
10.1038/nrd3078
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The pharmaceutical industry is under growing pressure from a range of environmental issues, including major losses of revenue owing to patent expirations, increasingly cost-constrained healthcare systems and more demanding regulatory requirements. In our view, the key to tackling the challenges such issues pose to both the future viability of the pharmaceutical industry and advances in healthcare is to substantially increase the number and quality of innovative, cost-effective new medicines, without incurring unsustainable R&D costs. However, it is widely acknowledged that trends in industry R&D productivity have been moving in the opposite direction for a number of years. Here, we present a detailed analysis based on comprehensive, recent, industry-wide data to identify the relative contributions of each of the steps in the drug discovery and development process to overall R&D productivity. We then propose specific strategies that could have the most substantial impact in improving R&D productivity.
引用
收藏
页码:203 / 214
页数:12
相关论文
共 45 条